By Fineline Cube Qyuns Therapeutics Co., Ltd. (HKG: 2509) announced that its wholly-owned subsidiary Qyuns Safe Biology Medicine Co., Ltd. has entered into an equity transfer agreement to acquire an approximately 34.0001% equity stake in Cellularforce from Taizhou Huacheng Medical Investment Group Co., Ltd. for RMB 86.02 million ($11.9 million), achieving 100% indirect ownership of the critical CMC (Chemistry, Manufacturing, and Controls) subsidiary.
Transaction Overview
| Item | Detail |
|---|---|
| Acquirer | Qyuns Safe Biology Medicine Co., Ltd. (wholly-owned subsidiary of Qyuns Therapeutics) |
| Target | Cellularforce (CMC-focused subsidiary) |
| Stake Acquired | 34.0001% equity interest |
| Transaction Value | RMB 86.02 million (approximately $11.9 million) |
| Post-Transaction Ownership | 100% indirect ownership through Safe Biology Medicine |
| Announcement Date | June 26, 2026 |
| Strategic Purpose | Facilitate NDA submissions for core pipeline products |
Subsidiary Profile: Cellularforce
- Primary Function: CMC (Chemistry, Manufacturing, and Controls) operations
- Core Capabilities:
- Cell line development
- Process development
- Formulation development
- Analytical method development
- Quality control (QC) and quality assurance (QA)
- Pilot production and commercial manufacturing
- Strategic Role: Central manufacturing and development platform for Qyuns’ antibody pipeline
- Integration Status: Will become fully integrated CMC arm under 100% Qyuns ownership
Cellularforce serves as the backbone of Qyuns’ biologics development infrastructure, providing end-to-end CMC capabilities essential for regulatory compliance and commercial-scale manufacturing of monoclonal antibodies.
Pipeline Impact & Regulatory Strategy
| Core Product | Target | Development Stage | CMC Dependency |
|---|---|---|---|
| QX002N | Anti-IL-17A monoclonal antibody | Pre-NDA | High – requires robust CMC package |
| Oturkibart (QX005N) | Anti-IL-4Rα monoclonal antibody | Pre-NDA | High – requires robust CMC package |
The acquisition directly supports Qyuns’ near-term regulatory objectives by ensuring complete control over the CMC components of New Drug Applications (NDAs) for both lead candidates. Full ownership eliminates potential coordination challenges with minority stakeholders during the critical NDA preparation and regulatory review phases.
Strategic Rationale & Market Context
| Strategic Driver | Analysis |
|---|---|
| Regulatory Control | Complete oversight of CMC data generation and submission processes |
| Operational Efficiency | Streamlined decision-making for manufacturing scale-up and process optimization |
| Intellectual Property Security | Enhanced protection of proprietary manufacturing processes and analytical methods |
| Commercial Readiness | Accelerated pathway to commercial manufacturing upon NDA approval |
| Investor Confidence | Demonstrates commitment to de-risking regulatory pathway for core assets |
China’s biologics market continues rapid growth, with monoclonal antibodies representing a significant segment. The IL-17A and IL-4Rα targets address substantial markets in autoimmune diseases, including psoriasis, atopic dermatitis, and asthma, with combined global market potential exceeding $20 billion annually.
Financial Structure & Integration Benefits
The RMB 86.02 million consideration represents a strategic investment that secures full control over critical manufacturing infrastructure. The transaction is expected to be immediately accretive by:
- Eliminating minority interest expenses
- Enabling optimal resource allocation across the CMC platform
- Accelerating NDA timelines through unified operational control
- Reducing regulatory risk through consistent quality systems
Forward-Looking Statements
This brief contains forward-looking statements regarding the acquisition, regulatory submissions, and commercial prospects of Qyuns’ pipeline. Actual results may differ due to risks including regulatory decisions, clinical outcomes, and competitive dynamics.-Fineline Info & Tech